PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer

Data from the Baltimore Longitudinal Study of Aging

Stacy Loeb, Anna Kettermann, Luigi Ferrucci, Patricia Landis, E. Metter, H. Ballentine Carter

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Our group has previously shown that prostate-specific antigen (PSA) velocity (PSAV) is associated with the presence of life-threatening prostate cancer. Less is known about the relative utility of pretreatment PSA doubling time (PSA DT) to predict tumor aggressiveness. Objective: To compare the utility of PSAV and PSA DT for the prediction of life-threatening prostate cancer. Design, setting, and participants: From the Baltimore Longitudinal Study of Aging, we identified 681 men with serial PSA measurements. Measurements: Receiver operating characteristic analysis was used to evaluate the relationship between PSAV, PSA DT, and the presence of high-risk disease. Results and limitations: Within the period of 5 yr prior to diagnosis, PSAV was significantly higher among men with high-risk or fatal prostate cancer than men without it. By contrast, PSA DT was not significantly associated with high-risk or fatal disease. On multivariate analysis, including age, date of diagnosis, and PSA, the addition of PSAV significantly improved the concordance index from 0.85 to 0.88 (p < 0.001), whereas PSA DT did not. Conclusions: These data suggest that PSAV is more useful than PSA DT in the pretreatment setting to help identify those men with life-threatening disease.

Original languageEnglish (US)
Pages (from-to)1073-1080
Number of pages8
JournalEuropean Urology
Volume54
Issue number5
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Baltimore
Prostate-Specific Antigen
Longitudinal Studies
Prostatic Neoplasms
ROC Curve
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer : Data from the Baltimore Longitudinal Study of Aging. / Loeb, Stacy; Kettermann, Anna; Ferrucci, Luigi; Landis, Patricia; Metter, E.; Carter, H. Ballentine.

In: European Urology, Vol. 54, No. 5, 01.11.2008, p. 1073-1080.

Research output: Contribution to journalArticle

Loeb, Stacy ; Kettermann, Anna ; Ferrucci, Luigi ; Landis, Patricia ; Metter, E. ; Carter, H. Ballentine. / PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer : Data from the Baltimore Longitudinal Study of Aging. In: European Urology. 2008 ; Vol. 54, No. 5. pp. 1073-1080.
@article{7abeb99b774e43f8b1c002afcccde104,
title = "PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging",
abstract = "Background: Our group has previously shown that prostate-specific antigen (PSA) velocity (PSAV) is associated with the presence of life-threatening prostate cancer. Less is known about the relative utility of pretreatment PSA doubling time (PSA DT) to predict tumor aggressiveness. Objective: To compare the utility of PSAV and PSA DT for the prediction of life-threatening prostate cancer. Design, setting, and participants: From the Baltimore Longitudinal Study of Aging, we identified 681 men with serial PSA measurements. Measurements: Receiver operating characteristic analysis was used to evaluate the relationship between PSAV, PSA DT, and the presence of high-risk disease. Results and limitations: Within the period of 5 yr prior to diagnosis, PSAV was significantly higher among men with high-risk or fatal prostate cancer than men without it. By contrast, PSA DT was not significantly associated with high-risk or fatal disease. On multivariate analysis, including age, date of diagnosis, and PSA, the addition of PSAV significantly improved the concordance index from 0.85 to 0.88 (p < 0.001), whereas PSA DT did not. Conclusions: These data suggest that PSAV is more useful than PSA DT in the pretreatment setting to help identify those men with life-threatening disease.",
author = "Stacy Loeb and Anna Kettermann and Luigi Ferrucci and Patricia Landis and E. Metter and Carter, {H. Ballentine}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.eururo.2008.06.076",
language = "English (US)",
volume = "54",
pages = "1073--1080",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer

T2 - Data from the Baltimore Longitudinal Study of Aging

AU - Loeb, Stacy

AU - Kettermann, Anna

AU - Ferrucci, Luigi

AU - Landis, Patricia

AU - Metter, E.

AU - Carter, H. Ballentine

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: Our group has previously shown that prostate-specific antigen (PSA) velocity (PSAV) is associated with the presence of life-threatening prostate cancer. Less is known about the relative utility of pretreatment PSA doubling time (PSA DT) to predict tumor aggressiveness. Objective: To compare the utility of PSAV and PSA DT for the prediction of life-threatening prostate cancer. Design, setting, and participants: From the Baltimore Longitudinal Study of Aging, we identified 681 men with serial PSA measurements. Measurements: Receiver operating characteristic analysis was used to evaluate the relationship between PSAV, PSA DT, and the presence of high-risk disease. Results and limitations: Within the period of 5 yr prior to diagnosis, PSAV was significantly higher among men with high-risk or fatal prostate cancer than men without it. By contrast, PSA DT was not significantly associated with high-risk or fatal disease. On multivariate analysis, including age, date of diagnosis, and PSA, the addition of PSAV significantly improved the concordance index from 0.85 to 0.88 (p < 0.001), whereas PSA DT did not. Conclusions: These data suggest that PSAV is more useful than PSA DT in the pretreatment setting to help identify those men with life-threatening disease.

AB - Background: Our group has previously shown that prostate-specific antigen (PSA) velocity (PSAV) is associated with the presence of life-threatening prostate cancer. Less is known about the relative utility of pretreatment PSA doubling time (PSA DT) to predict tumor aggressiveness. Objective: To compare the utility of PSAV and PSA DT for the prediction of life-threatening prostate cancer. Design, setting, and participants: From the Baltimore Longitudinal Study of Aging, we identified 681 men with serial PSA measurements. Measurements: Receiver operating characteristic analysis was used to evaluate the relationship between PSAV, PSA DT, and the presence of high-risk disease. Results and limitations: Within the period of 5 yr prior to diagnosis, PSAV was significantly higher among men with high-risk or fatal prostate cancer than men without it. By contrast, PSA DT was not significantly associated with high-risk or fatal disease. On multivariate analysis, including age, date of diagnosis, and PSA, the addition of PSAV significantly improved the concordance index from 0.85 to 0.88 (p < 0.001), whereas PSA DT did not. Conclusions: These data suggest that PSAV is more useful than PSA DT in the pretreatment setting to help identify those men with life-threatening disease.

UR - http://www.scopus.com/inward/record.url?scp=55649123911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649123911&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2008.06.076

DO - 10.1016/j.eururo.2008.06.076

M3 - Article

VL - 54

SP - 1073

EP - 1080

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -